- Report
- February 2025
- 200 Pages
Global
From €4008EUR$4,490USD£3,507GBP
- Report
- March 2025
- 150 Pages
Global
From €3437EUR$3,850USD£3,007GBP
€4330EUR$4,850USD£3,788GBP
- Report
- August 2025
- 383 Pages
Global
From €5223EUR$5,850USD£4,569GBP
- Report
- April 2025
- 150 Pages
Global
From €3437EUR$3,850USD£3,007GBP
€4330EUR$4,850USD£3,788GBP
- Drug Pipelines
- April 2025
- 70 Pages
Global
From €1339EUR$1,500USD£1,172GBP
- Report
- May 2025
- 184 Pages
Global
From €3165EUR$3,545USD£2,769GBP
€3517EUR$3,939USD£3,077GBP
- Report
- May 2025
- 188 Pages
Global
From €3165EUR$3,545USD£2,769GBP
€3517EUR$3,939USD£3,077GBP
- Report
- May 2025
- 198 Pages
Global
From €3165EUR$3,545USD£2,769GBP
€3517EUR$3,939USD£3,077GBP
- Report
- May 2025
- 184 Pages
Global
From €3165EUR$3,545USD£2,769GBP
€3517EUR$3,939USD£3,077GBP
- Report
- May 2025
- 191 Pages
Global
From €3165EUR$3,545USD£2,769GBP
€3517EUR$3,939USD£3,077GBP
- Report
- February 2025
- 200 Pages
Global
From €4008EUR$4,490USD£3,507GBP
- Report
- December 2024
- 200 Pages
Global
From €2232EUR$2,500USD£1,953GBP
- Report
- August 2025
- 266 Pages
Global
From €5223EUR$5,850USD£4,569GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1785EUR$2,000USD£1,562GBP
- Report
- August 2024
- 137 Pages
Global
From €2677EUR$2,999USD£2,342GBP
- Report
- August 2025
- 391 Pages
Global
From €5223EUR$5,850USD£4,569GBP
- Report
- January 2025
- 183 Pages
Global
From €4017EUR$4,500USD£3,515GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1339EUR$1,500USD£1,172GBP
- Report
- November 2024
- 203 Pages
Global
From €3973EUR$4,450USD£3,476GBP
- Report
- March 2025
- 150 Pages
Global
From €3437EUR$3,850USD£3,007GBP
€4330EUR$4,850USD£3,788GBP

The Carbapenem market is a subset of the Antibiotics market, which is composed of drugs used to treat bacterial infections. Carbapenems are a class of antibiotics that are used to treat serious infections caused by bacteria that are resistant to other antibiotics. They are typically used as a last resort when other antibiotics have failed. Carbapenems are generally well-tolerated and have a low risk of side effects.
Carbapenems are used to treat a wide range of infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. They are also used to treat infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
The Carbapenem market is highly competitive, with several major players. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Novartis, and Daiichi Sankyo. Show Less Read more